Polycystic ovary syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome
Conditions
Interventions
Intervention 1: A. Outcome measurement, 6 months of treatment with Ovustop-L, outcome measurement in the end of third and six months of treatment, a washout period for 6 weeks, Outcome measurement, th
Treatment - Drugs
A. Outcome measurement, 6 months of treatment with Ovustop-L, outcome measurement in the end of third and six months of treatment, a washout period for 6 weeks, Outcome measurement, the second treatme
B. Outcome measurement, 6 months of treatment with Contrasmine, outcome measurement in the end of third and six months of treatment, a washout period for 6 weeks, Outcome measurement, the second treat
C. Outcome measurement, 6 months of treatment with Ovustop-L, outcome measurement in the end of third and six months of treatment, a washout period for 6 weeks, Outcome measurement, the second treatme
D. Outcome measurement, 6 months of treatment with Etisterone, outcome measurement in the end of third and six months of treatment, a washout period for 6 weeks, Outcome measurement, the second treatm
E. Outcome measurement, 6 months of treatment with Ovustop-L, outcome measurement in the end of third and six months of treatment, a washout period for 6 weeks, Outcome measurement, the second treatme
F. Outcome measurement, 6 months of treatment with Desoceptive, outcome measurement in the end of third and six months of treatment, a washout period for 6 weeks, Outcome measurement, the second treat
Sponsors
Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: Existent of diagnostic criteria for polycystic ovary syndrome based on Androgen Excess and PCOS Society (AES), Lack of pregnancy diagnosis and tendency to it for a year or more, lack of using hormonal, anti-androgens or sensitizers drugs at least 3 months before the study, Failure to detect other causes of hyperandrogenism, Not having chronic medical conditions, high and severe blood pressure, recent surgery or known cancer, 6- Not smoking and non-obesity. Exclusion criteria: Not adherence to prescribed medications for more than two months, detection of chronic medical disorders, Appearing the serious effects such as thrombosis contraceptive.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Free Androgen Index (FAI). Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: According to the formula of total testosterone (nmol/ L)) x 100 /sex hormone-binding globulin). | — |
Secondary
| Measure | Time frame |
|---|---|
| Hirsutism. Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: Ferriman- Galwey scoring system.;Body mass index (BMI). Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: kg/m2.;Acne. Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: Wang criteria.;Alopecia. Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: Ludwig criteria.;Menstruation cycles pattern. Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: questionnaire.;Insulin resistance. Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: Electrochemilumniscen immuno assay.;Fasting blood sugar (FBS). Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: Enzymatic colorimetric.;(TG) triglyceride. Timepoint: (Before treatment, 3 months after first treatment, 6 months after first treatment, after wash-out, 3 months after second treatment, 6 months after second treatment). Method of measurement: Calorimetric.;Total Cholesterol. Timepoint: (Before treatment, 3 months after first treatment, 6 months afte | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFahimeh Ramezani Tehrani
Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences ShahidBeheshti
Outcome results
None listed